# US 2014/0155614 A1 · Pharmaceutical intermediates and process for the preparation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155614 A1
- Document ID: US20140155614A1
- Status: Published application
- Kind: A1
- Application number: 14/116,464
- Filed: 2012-05-10
- Published: 2014-06-05
- Earliest claimed: 2011-05-11
- Assignees: Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag
- Inventors: Imre Kiraly; Tibor Szabo; Gyula Simig; Balazs Volk; Laszlo Szlavik; Jozsef Barkoczy; Gyorgy Ruzsics; Gyula Lukacs; Laszlo Pongo; Andras Boza; Maria Tothne Lauritz; Maria Kovacs
- Web page: https://patentgrep.com/patent/US20140155614A1

## CPC

- C07D 413/14: containing three or more hetero rings
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to a process for the preparation of dabigatran etexilate of the formula or pharmaceutically accepted salts thereof.

## Claims

### Claim 1

Process for the preparation of dabigatran etexilate of the Formula
or pharmaceutically acceptable salts thereof
which comprises reducing a compound of the general Formula
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl
optionally converting the compound of the Formula
thus obtained into a salt and
reacting the compound of the Formula (2) or a salt thereof with chloro hexyl formate to yield the compound of the Formula (1) and
optionally forming a salt from the compound of the Formula (1).

### Claim 2 (depends on 1)

Process according to claim 1 which comprises carrying reduction by means of catalytic hydrogenation, preferably with a palladium charcoal catalyst, in the presence of an acid, advantageously acetic acid.

### Claim 3 (depends on 1)

Process according to claim 1 which comprises adding for the formation of a salt of the compound of the Formula (2) if necessary a further acid, preferably p-toluenesulfonic acid, advantageously in a 2-6 molar equivalent, particularly in 2-4 molar equivalent amount to yield the ditosylate salt of the compound of the Formula (2).

### Claim at position 4

4-15. (canceled)

### Claim 16

A product, which is
the 1:2 p-toluenesulfonic acid salt of ethyl-N-[(2-{[(4-carbamimidoylphenyl)-amino]-methyl}-1-methyl-1H-benzimidazole-5-yl)-carbonyl]-N-pyridine-2-yl-β-alaninate (2); or
the 1:2 acetic acid salt of ethyl-N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-yl)-carbonyl]-N-pyridine-2-yl-β-alaninate (2); or
a compound of the general Formula (15)
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl
or a salt thereof; or
the monooxalate salt of a compound of the general Formula (15)
wherein
R is methyl; or
a compound of the general Formula (14)
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl,
or a salt thereof; or
a compound of the general Formula (13)
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl,
R″ stands for
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl or
aralkyl,
or a salt thereof.

### Claim 17 (depends on 16)

A product according to claim 16, which is the 1:2 p-toluenesulfonic acid salt of ethyl-N-[(2-{[(4-carbamimidoylphenyl)-amino]-methyl}-1-methyl-1H-benzimidazole-5-yl)-carbonyl]-N-pyridine-2-yl-β-alaninate (2).

### Claim 18 (depends on 16)

A product according to claim 16, which is the 1:2 acetic acid salt of ethyl-N-[(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-yl)-carbonyl]-N-pyridine-2-yl/-β-alaninate (2).

### Claim 19 (depends on 16)

A product according to claim 16, which is a compound of the general Formula (15)
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl,
or a salt thereof.

### Claim 20 (depends on 16)

A product according to claim 16, which is the monooxalate salt of a compound of the general Formula (15)
wherein
R is methyl.

### Claim 21 (depends on 16)

A product according to claim 16, which is a compound of the general Formula (14)
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl,
or a salt thereof.

### Claim 22 (depends on 16)

A product according to claim 16, which is a compound of the general Formula (13)
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl,
R″ stands for
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl or
aralkyl,
or a salt thereof.

### Claim 23 (depends on 19)

Process for the preparation of a compound according to claim 19 or a salt thereof which comprises coupling a compound of the general Formula
or a salt thereof
wherein
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl,
with the compound of the Formula
and carrying out ring closure of the benzimidazole ring.

### Claim 24 (depends on 23)

Process according to claim 23 which comprises carrying out coupling and ring-closure in a one-step process, preferably by using an acylation promoter, particularly 1,1′-carbonyl-diimidazole (CDI) or propyl phosphonic acid anhydride (T3P).

### Claim 25 (depends on 21)

Process for the preparation of a compound according to claim 21 or a salt thereof which comprises reacting, as a starting material, a compound of the general Formula
or a salt thereof
R stands for hydrogen;
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl;
aryl or
methoxymethyl, and
R″ stands for
C1-6 straight or branched chain, saturated or partially or completely un-saturated hydrocarbon chain,
C1-6 straight or branched chain, partially or completely halogenated alkyl or
aralkyl.

### Claim 26 (depends on 25)

Process according to claim 25 which comprises carrying out ester hydrolysis under acidic or alkaline conditions, preferably in alkaline medium, particularly with an alkali hydroxide.

### Claim 27 (depends on 22)

Process for the preparation of a compound of the general Formula 13 according to claim 22 or a salt thereof which comprises reacting a compound of the general Formula (12)
wherein R has the same meaning as in the compound of Formula 13
with a halogen acetic acid alkyl ester.

### Claim 28 (depends on 27)

Process according to claim 27 which comprises carrying out the reaction with bromo ethyl acetate or chloro ethyl acetate, preferably with bromo ethyl acetate and using an organic or inorganic base, preferably Hunig-base or triethyl amine as acid binding agent.
